RARE

#1846
Ultragenyx Pharmaceutical Inc.
24.57 USD
+3.98%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
24.57
24.57
1年のレンジ
18.29
42.37
1日の変化
+3.98%
月次変化
+13.91%
6か月変化
-22.66%
1年の変化
-29.72%
以前の終値
23.63
始値
24.57
Bid
Ask
安値
24.57
High
24.57
ボリューム
97
チャート全体を表示

Financials

概要 明細書 統計
期次 年次
  • Market Capitalization 2.37 B
  • Employee 1 371
  • Founded 2010
  • CEO Emil Kakkis
  • Website www.ultragenyx.com
  • Headquarter Delaware, United States
  • FIGI BBG001RWPDW6
  • Industry Technology
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-3.95
売上高対価格比率
3.37

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

ニュース